急性肺栓塞后残余肺血管阻塞与复发:个体参与者数据的系统评价与荟萃分析
该系统评价与荟萃分析纳入809例首次急性肺栓塞患者,评估完成至少3个月抗凝治疗后平面肺扫描所示残余肺血管阻塞(RPVO)与停药后1年复发性静脉血栓栓塞或肺栓塞所致死亡的关系。RPVO是复发性静脉血栓栓塞风险的显著预测因素,但无残余灌注缺损患者的复发风险仍过高,不能单独用于决定是否停用抗凝。
要点
- 完成至少3个月抗凝后,407例(50.3%)存在RPVO(阻塞>0%)。
- RPVO<5%者1年复发VTE风险为5.8%(95%CI 4.4-7.2),RPVO≥5%者为11.7%(95%CI 9.5-13.8)。
- RPVO是复发性VTE的显著预测因素,但无残余灌注缺损者风险仍过高,不宜单独据此停药。
核心结论
- RPVO是复发性静脉血栓栓塞风险的显著预测因素。
- 无残余灌注缺损患者的复发风险仍过高,不能单独用于决定停用抗凝。
研究设计与样本
- 系统评价与个体参与者数据荟萃分析,注册号PROSPERO CRD42017081080。
- 获得809例首次急性肺栓塞患者的个体数据,抗凝治疗中位6.6个月后行平面肺扫描。
主要发现
- 407例(50.3%)存在RPVO(阻塞>0%)。
- 114例(14.1%)发生复发性VTE或肺栓塞所致死亡,年风险6.4%(95%CI 4.7%-8.6%)。
- 114例复发事件中63例发生在停用抗凝后1年内,1年风险8.1%(95%CI 6.4%-9.8%)。
- RPVO<5%者1年复发VTE风险5.8%(95%CI 4.4-7.2),RPVO≥5%者为11.7%(95%CI 9.5-13.8)。
临床怎么用
- 原文结论未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We aimed to assess the relationship between residual pulmonary vascular obstruction (RPVO) on planar lung scan after completion of at least 3 months of anticoagulant therapy for acute pulmonary embolism (PE) and the risk of recurrent venous thromboembolism (VTE) or death due to PE one year after treatment discontinuation. The systematic review was registered with the International Prospective Registry of Systematic Reviews (PROSPERO: CRD42017081080). The primary outcome measure was to generate a pooled estimate of the rate of recurrent VTE at one year in patient with RPVO diagnosed on planar lung scan after discontinuation of at least 3 months of anticoagulant treatment for an acute PE. Individual data were obtained for 809 patients. RPVO (ie, obstruction >0%) was found in 407 patients (50.3%) after a median of 6.6 months of anticoagulant therapy for a first acute PE. Recurrent VTE or death due to PE occurred in 114 patients (14.1%), for an annual risk of 6.4% (95% confidence interval, 4.7%-8.6%). Out of the 114 recurrent events, 63 occurred within one year after discontinuation of anticoagulant therapy corresponding to a risk of 8.1% (6.4%-9.8%) at 1 year. The risk of recurrent VTE at one year was 5.8% (4.4-7.2) in participants with RPVO <5%, vs 11.7% (9.5-13.8) in participants with RPVO ≥5%. RPVO is a significant predictor of the risk of recurrent venous thromboembolism. However, the risk of recurrent events remains too high in patients without residual perfusion defect for it to be used as a stand-alone test to decide on anticoagulation discontinuation.
引用
- Robin P, Le Pennec R, Eddy M, et al. Residual pulmonary vascular obstruction and recurrence after acute pulmonary embolism: a systematic review and meta-analysis of individual participant data. J Thromb Haemost. 2023. PMID: 36740040. doi:10.1016/j.jtha.2023.01.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。